Cart
sales@molnova.com
Lirilumab
CAS No. 1000676-41-4
Lirilumab( —— )
Catalog No. M36889 CAS No. 1000676-41-4
Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 440 | In Stock |
|
| 10MG | 692 | In Stock |
|
| 25MG | 1026 | In Stock |
|
| 50MG | 1376 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLirilumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition.
-
DescriptionLirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
-
In Vitro——
-
In VivoLirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor.Animal Model:Rag1KO-Tg KIR mice injected with tumor cells Dosage:15 mg/kg Administration:intravenous injection; 15 mg/kg; once Result:Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorVirus Protease
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1000676-41-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478.?
molnova catalog
related products
-
13-Oxyingenol dodeca...
13-Oxyingenol-dodecanoate (13OD) is a tumor suppressor agent. 13-Oxyingenol-dodecanoate has anti-HIV-1 activity with EC50 value of 33.7 nM.13-Oxyingenol-dodecanoate can induce the expression of ULK1 to effect mitochondrial dysfunction and cellular autophagy. 13-Oxyingenol-dodecanoate also increases the expression of BAX and suppresses the expression of BCL-2 to effect apoptosis.
-
tafamidis meglumine
Tafamidis meglumine is a Potent and Selective Transthyretin Kinetic Stabilizer That Inhibits the Amyloid Cascade.
-
5,6,7,3',4'-Pentamet...
5,6,7,3',4'-pentamethoxyflavanone exhibited anti-proliferative activities.
